Recombinant adenoassociated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. Here, we present:
- Optimization strategies for AAV and LV generation in both adherent and suspension HEK 293 cells
- LV and AAV enhancers that further increase functional virus titers over previously optimized conditions
- How TransIT-VirusGENÂ® Transfection Reagent and Kits can expand manufacturing capabilities for gene and cell therapies
Just fill out the form below to watch the recorded webcast.